Evidence map›Paper›PMID 40538293›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines.

Jiameng Li, Ya-Li Zhang, Tong Jin, Zhaokui Jin, Mengliang Zhu, Guangchao Qing, Jinchao Zhang, Zhisen Wang, Yan Mu, Jin Li and 2 more

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Engineered bone-targetingMaterials today. Bio · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiameng LiState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the Key Laboratory of Advanced Interdisciplinary Studies, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Ya-Li ZhangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing, 100190, China.
Tong JinSchool of Life Sciences, Beijing University of Chinese Medicine, Beijing, 102488, China.
Zhaokui JinSchool of Biomedical Engineering, Guangzhou Medical University, Guangzhou, 511436, China.
Mengliang ZhuCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing, 100190, China.
Guangchao QingCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing, 100190, China.
Jinchao ZhangCollege of Chemistry & Materials Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education, Chemical Biology Key Laboratory of Hebei Province, Hebei University, Baoding, 071002, China.
Zhisen WangShijiazhuang Zangnuo Tibetan Medicine Research Institute, Shijiazhuang, 051430, China.
Yan MuCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing, 100190, China.
Jin LiState Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, the Key Laboratory of Advanced Interdisciplinary Studies, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China.
Qian HuaSchool of Life Sciences, Beijing University of Chinese Medicine, Liangxiang Higher Education Park, Beijing, 47839, China.
Xing-Jie LiangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing, 100190, China.ORCID 0000-0002-4793-1705

Funding

Chinese Academy of Sciences CAS-NSTDAGuang Dong Basic and Applied Basic Research Foundation 2024A1515030203Guangzhou Science and Technology Bureau Basic Research Program City School Enterprise Joint Funding Project 2025A03J4530International Partnership Program 121D11KYSB20210003NSFC key project 32030060NSFC key project 82430067Science and Technology Innovation Committee Joint Funding (Dengfeng Hospital) Project of Guangzhou 2023A03J0355Science Fund for Creative Research Groups of Nature Science Foundation of Hebei Province B2021201038
6 · The paper itself

Abstract

Over centuries of clinical practice, Chinese herbal medicines (CHMs) have gained widespread recognition for their efficacy in treating various diseases. However, their complex material basis and relatively mild therapeutic efficacy limit their modernization and quality control. Recently, the application of pharmaceutical nanotechnology to CHMs has not only enhanced their efficacy, but also helped elucidate their material basis, thereby substantially advancing their modernization. Nano-modified CHMs have shown improvements in multiple aspects, such as bioavailability, targeting ability, toxicity reduction, and sustained release. In this review, nano-strategies for emerging, revolutionary, and promising pathways for modernizing CHMs are revealed. First, the development, application potential, particularities, and limitations of CHMs are reviewed. Subsequently, a systematic and comprehensive analysis of the two nano-strategies for optimizing CHMs are presented, highlighting the distinct characteristics of the carrier-free and carrier-based approaches. The specific advantages of these strategies, including improved bioavailability, increased targeting ability, reduced toxicity, and controlled release, are discussed. The novel research directions resulting from the application of pharmaceutical nanotechnology to CHMs are also explored, such as elucidating CHM treatment theories, combining traditional Chinese medicine topical therapies, drug screening, and expanding innovative drug formulations. Finally, the challenges and opportunities in this field are addressed to inspire future research.

Indexed as

Drugs, Chinese HerbalMedicine, Chinese TraditionalNanotechnologyTechnology, PharmaceuticalAnimalsDrug Delivery SystemsHumansDrugs, Chinese Herbalbioactive materialschinese herbal medicinesmaterial basisnanocarriersself‐assembly

Identifiers

PMID40538293
PMCPMC12376714

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.